HELP YOUR PATIENTS SAVE MONEY

A switch to FIBRICOR® can save patients money

  • FIBRICOR is a low-cost alternative to TriCor® or Trilipix®
  • Many patients can have their FIBRICOR prescription filled affordably with a generic at a Tier-1 copay

For your patients who need fibrate therapy, remember to write FIBRICOR — the better-value fibrate.

Important Safety Information HCP

FIBRICOR® is contraindicated in patients with severe renal impairment including those on dialysis, with active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities and with gallbladder disease. FIBRICOR is also contraindicated in nursing mothers and patients with hypersensitivity to fenofibric acid, choline fenofibrate or fenofibrate.

The most commonly reported adverse reactions (> 2% and greater than placebo) are increases in liver test values, abdominal pain, back pain, and headache.

Fenofibrate can increase serum transaminases, so patients should be monitored for AST or ALT changes periodically for the duration of the therapy. In addition, myopathy and rhabdomyolysis have been reported in patients taking fenofibrate. The risks of myopathy and rhabdomyolysis may be increased in patients who are elderly, have diabetes, renal failure, or hypothyroidism. Patients should be advised to report unexplained muscle pain, tenderness or weakness promptly, especially if accompanied by malaise or fever. Creatine phosphokinase (CPK) levels should be assessed in these patients. Fenofibrate can reversibly increase serum creatinine levels. Patients with renal impairment and those at risk for renal insufficiency should be periodically monitored. Fenofibrate increases cholesterol excretion into the bile, leading to risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

References: 1. Data on file, URL Pharma, Inc. 2. Fibricor [package insert]. Philadelphia, PA: URL Pharma, Inc.; 2009. 3. Trilipix [package insert]. North Chicago, IL: Abbott Laboratories; 2008. 4. TriCor [package insert]. North Chicago, IL: Abbott Laboratories; 2008. 5. Dorland's Illustrated Medical Dictionary. 28th ed. Philadelphia, PA: W.B. Saunders Company; 1994.

TriCor® and Trilipix® are registered trademarks of Fournier Industrie et Santé Corporation, France.